News

Corbus Initiates Phase 2 Trial Evaluating Anabasum to Treat Lupus Patients

Corbus Pharmaceuticals recently started a Phase 2 clinical trial evaluating anabasum as an investigational therapy for the treatment of systemic lupus erythematosus (SLE). Anabasum is a synthetic endocannabinoid mimetic drug, meaning it mimics the action of endocannabinoids, which are endogenous molecules that bind to cannabinoid receptors in the nervous system. The drug…

Lupus Patients More Likely to Develop Atherosclerosis, Study Suggests

Patients with systemic lupus erythematosus (SLE) have higher incidence of subclinical atherosclerosis markers compared to heathy people, a French study shows. Understanding how cardiovascular disease develops in lupus patients may help establish better, personalized therapeutic strategies, including in patients who have no history of cardiovascular disease. The study, “…

Oklahoma Foundation Launches First Lupus Prevention Study

The Oklahoma Medical Research Foundation (OMRF) recently launched the world’s first lupus prevention study, known as the SMILE clinical trial. The Phase 2 study (NCT03030118) seeks to identify individuals at high risk for developing lupus and treat them with an immune-modifying medication before they develop the disease. The overarching…